PDF(Pubmed)
Abstract：
The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect to susceptibility to β-lactam/β-lactamase inhibitor combinations including ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and to cefiderocol. A large series of E. coli recombinant strains producing broad-spectrum β-lactamases was evaluated. While imipenem-relebactam showed a similar activity regardless of the PBP3 background, susceptibility to other molecules tested was affected at various levels. This was particularly the case for ceftazidime-avibactam, aztreonam-avibactam, and cefepime-taniborbactam.
摘要：
评估了可能在大肠杆菌中鉴定的青霉素结合蛋白3（PBP3）修饰对β-内酰胺/β-内酰胺酶抑制剂组合（包括头孢他啶-阿维巴坦）的敏感性的影响，亚胺培南-莱巴坦,美罗培南-瓦巴坦,氨曲南-阿维巴坦,头孢吡肟-坦尼博巴坦,还有塞菲德罗。评价了一系列产生广谱β-内酰胺酶的大肠杆菌重组菌株。尽管亚胺培南-瑞巴坦显示出相似的活性，但无论PBP3背景如何，对其他测试分子的敏感性受到不同水平的影响。头孢他啶-阿维巴坦的情况尤其如此，氨曲南-阿维巴坦,还有头孢吡肟-坦尼博巴坦.
